Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
Dyslipidemia: Current Therapies and Guidelines for Treatment
Author(s): Edward T Carreras , Donna M Polk Added: 3 years ago
Cardiovascular disease affects more than one-third of American adults and is the leading cause of mortality in the United States and worldwide.1 Only 4.5 % of those over the age of 20 meet the ideal levels of the seven metrics of cardiovascular health including cholesterol levels.1 Of modifiable risk factors, including smoking, hypertension, diabetes, and obesity, dyslipidemia has been shown to… View more

Prevention & Chronic Conditions
Author(s): Sergio Fazio Added: 3 years ago
The wide utilization of anti-cholesterol agents, such as the statins, has created confusion among patients and clinicians about what to do when the lipid problem is one of triglycerides and high-density lipoprotein (HDL), rather than one of low density lipoprotein (LDL). Although most patients with diabetes have a dyslipidemia characterized by high triglycerides and low HDL (atherogenic… View more

Prevention & Chronic Conditions
Author(s): Sergio Fazio Added: 3 years ago
Current Indications for Statin and Fibrate Therapy The evidence of cardiovascular protection afforded by statins has recently extended beyond patients with hypercholesterolemia. With the publication of several trials,1-7 bold extrapolations of the power of statin therapy in cardiovascular prevention have been offered: statins equally reduce risk in subjects with or without… View more

Prevention & Chronic Conditions
Author(s): Sergio Fazio Added: 3 years ago
Current Indications for Statin and Fibrate Therapy The evidence of cardiovascular protection afforded by statins has recently extended beyond patients with hypercholesterolemia. With the publication of several trials,1-7 bold extrapolations of the power of statin therapy in cardiovascular prevention have been offered: statins equally reduce risk in subjects with or without… View more

Prevention & Chronic Conditions
Author(s): Mohit Gupta , Borut Jug , Matthew J Budoff Added: 3 years ago
Diabetes and Cardiovascular Disease Diabetes has long been recognized as a major risk factor for cardiovascular disease and is widely regarded as a ‘coronary disease equivalent,’1,2 as diabetes and established coronary heart disease indicate a similar absolute risk for cardiovascular death in both men and women.3–5 Cardiovascular complications of diabetes have traditionally been regarded as… View more

Prevention & Chronic Conditions
Specialist in Internal Medicine with special training in hypertension and dyslipidemia and a genuine passion for preventive medicine; lecturer at the University of Zürich and PhD in cardiovascular research. Head of the hypertension and dyslipidemia facilities of the heart center and of the smoking cessation clinic of the university Hospital Zurich. Her research focuses on vascular research … View more
Author(s): Sergio Fazio Added: 3 years ago
Introduction The main controversy in the area of lipid management today is related to the usefulness of 'non-statin’ agents to maximize cardiovascular risk reduction in particular patient types, such as those with diabetes and metabolic syndrome. Fibrate drugs, such as gemfibrozil (Lopid) and fenofibrate (TriCor), are undoubtedly the best tools to address the condition characterized by high… View more

Prevention & Chronic Conditions
Author(s): Sergio Fazio Added: 3 years ago
Introduction The main controversy in the area of lipid management today is related to the usefulness of 'non-statinÔÇÖ agents to maximize cardiovascular risk reduction in particular patient types, such as those with diabetes and metabolic syndrome. Fibrate drugs, such as gemfibrozil (Lopid) and fenofibrate (TriCor), are undoubtedly the best tools to address the condition characterized by high… View more

Prevention & Chronic Conditions
AHA 2020: The STRENGTH Trial
Author(s): A Michael Lincoff Added: 3 years ago
Dr A Michael Lincoff (Cleveland Clinic, Cleveland, OH, US) discusses the results from the STRENGTH trial which assessed potential benefits of Epanova (omega-3 carboxylic acids) with placebo (corn oil), for the reduction of major adverse CV events in patients with mixed dyslipidaemia and at high risk for CVD who were already on optimal statin therapy. Results showed a low likelihood of benefit to… View more

Prevention & Chronic Conditions
Author(s): Peter H Jones Added: 3 years ago
High Residual Cardiovascular Risk in Diabetic Patients Treated with Statins According to the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATPIII), diabetes is a coronary heart disease (CHD) risk equivalent.1 One major factor contributing to the excess risk of cardiovascular disease (CVD) in patients with type 2 diabetes mellitus (T2DM) is atherogenic dyslipidemia,… View more

Prevention & Chronic Conditions